Top

Cancer Immunology, Immunotherapy

Published in:

01-07-2018 | Letter to the Editors

The role of myeloid derived suppressor cells in mycosis fungoides

Authors: Alessandro Pileri, Claudio Agostinelli, Pietro Quaglino, Annalisa Patrizi, Nicola Pimpinelli

Published in: Cancer Immunology, Immunotherapy | Issue 7/2018

Excerpt

Dear Editors, …

Geskin LJ, Akilov OE, Kwon S, Schowalter M, Watkins S, Whiteside TL, Butterfield LH, Falo LD Jr (2018) Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome. Cancer Immunol Immunother 67(3):423–434. https://doi.org/10.1007/s00262-017-2090-z CrossRefPubMed

Pileri A, Agostinelli C, Sessa M, Quaglino P, Santucci M, Tomasini C, Grandi V, Fava P, Astrua C, Righi S, Patrizi A, Pileri SA, Pimpinelli N (2017) Langerhans, plasmacytoid dendritic and myeloid-derived suppressor cell levels in mycosis fungoides vary according to the stage of the disease. Virchows Arch 470(5):575–582. https://doi.org/10.1007/s00428-017-2107-1 CrossRefPubMed

Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9(3):162–174. https://doi.org/10.1038/nri2506 CrossRefPubMedPubMedCentral

Sasso MS, Lollo G, Pitorre M, Solito S, Pinton L, Valpione S, Bastiat G, Mandruzzato S, Bronte V, Marigo I, Benoit JP (2016) Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy. Biomaterials 96:47–62. https://doi.org/10.1016/j.biomaterials.2016.04.010 CrossRefPubMed

He W, Liang P, Guo G, Huang Z, Niu Y, Dong L, Wang C, Zhang J (2016) Re-polarizing myeloid-derived suppressor cells (MDSCs) with cationic polymers for cancer immunotherapy. Sci Rep 6:24506. https://doi.org/10.1038/srep24506 CrossRefPubMedPubMedCentral

Title: The role of myeloid derived suppressor cells in mycosis fungoides
Authors: Alessandro Pileri
Claudio Agostinelli
Pietro Quaglino
Annalisa Patrizi
Nicola Pimpinelli
Publication date: 01-07-2018
Publisher: Springer Berlin Heidelberg
Published in: Cancer Immunology, Immunotherapy / Issue 7/2018
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-018-2153-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 7/2018

Quantifying tumor-infiltrating immune cells from transcriptomics data

Regulatory NK1.1−CD4+NKG2D+ subset induced by NKG2DL+ cells promotes tumor evasion in mice

Genetic variants in the HLA class II region associated with risk of cutaneous squamous cell carcinoma

VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival

T-lymphocyte profiles differ between keratoacanthomas and invasive squamous cell carcinomas of the human skin

Pushing the limits of immune-related response: a case of “extreme pseudoprogression”

Keynote webinar | Spotlight on antibody–drug conjugates in cancer